Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

2804 - Preoperative C-reactive protein and thrombocyte count as potential markers for longterm survival in ovarian cancer

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Translational Research

Tumour Site

Ovarian Cancer

Presenters

Elena Ioana Braicu

Citation

Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. 10.1093/annonc/mdy285

Authors

E.I. Braicu1, J. Sehouli2, R. Richter3, I.B. Vergote4, N. Concin5, E. van Nieuwenhuysen4, P. Achimas6, A. Berger7, B. Fetica6, S. Mahner8, J. Glajzer2, A. Papadia9, L. Woelber10, M.L. Gasparri11, A. Vanderstichele12, P. Benedetti Panici13, M. Mueller11, I. Ruscito2, J. Zimmer3, H. Woopen1

Author affiliations

  • 1 Department For Gynecology, Charité - Universitätsmedizin Berlin, 10117 - Berlin/DE
  • 2 Department For Gynecology, Universitätsklinik Charité, Campus Virchow Klinikum, 13353 - Berlin/DE
  • 3 Gynecology, Universitätsklinik Charité, Campus Virchow Klinikum, 13353 - Berlin/DE
  • 4 Gynaecology, University Hospitals Leuven, 3000 - Leuven/BE
  • 5 Department Of Gynecology, University Hospitals Leuven, 3000 - Leuven/BE
  • 6 Gynecological Oncology, Oncological Institute Ion Chiricuta, 400462 - Cluj-Napoca/RO
  • 7 Department Of Obstetrics And Gynecology, Innsbruck Medical University, Innsbruck/AT
  • 8 Gynaecology, AGO Study Group & University Medical Center Hamburg-Eppendorf and University of Munich; current address University of Munich, 81377 - München/DE
  • 9 Department Of Obstetrics And Gynecology, University of Bern and Inselspital University Hospital, Bern/CH
  • 10 Department For Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg/DE
  • 11 Department Of Obstetrics And Gynecology, University of Bern and Inselspital University Hospital of Bern, Bern/CH
  • 12 Gynaecological Oncology, University Hospitals Leuven, 3000 - Leuven/BE
  • 13 Department Of Gynecology And Obsetrics, Universita La Sapienza, 00185 - Roma/IT
More

Abstract 2804

Background

Aim of this study was to evaluate the predictive role for C-reactive protein (CRP) and thrombocyte count as surrogate markers for the interleukin-6 pathway for longterm survival with ovarian cancer.

Methods

Patients and methods: Within the tumorbank ovarian cancer (TOC) preoperative CRP values and thrombocyte counts were collected for longterm survivors (survival of ≥ 8 years after initial diagnosis) from seven gynecologic-oncology centers as well as classical ovarian cancer patients diagnosed in the same timeframe (survival < 5 years after initial diagnosis). Receiver operating characteristics (ROC) curves and logistic regression analyses were conducted to evaluate differences between cohorts.

Results

In this study 336 longterm survivors (LTS) and 172 control patients could be included. There was no difference in preoperative thrombocyte count with a median of 326/nl in LTS (n = 136) vs. 325/nl in control patients (n = 151), p = 0.59. Regarding preoperative CRP values at initial diagnosis there was a significant difference in both univariate and multivariate analyses: Median CRP was 9.2 mg/l in LTS (n = 56) compared to 18.4 mg/l in control patients (n = 85), p = 0.002. ROC-curves showed an area under the curve of 0.66 (95% CI 0.56-0.75), p = 0.002. After adjusting for age, FIGO stage, grading and histology there was still a significant difference between the two cohorts (p = 0.002). Patients with CRP <1.3 mg/l had a 15-fold higher chance to survive longer than eight years compared to patients with a CRP >40 mg/l at initial diagnosis (p = 0.001, 95% CI 3.3-70.5).

Conclusions

Preoperative C-reactive protein was significantly lower in longterm survivors compared to classical ovarian cancer patients indicating the potential role of CRP as prognostic marker for longterm survival. Further studies are highly warranted in order to gain more insight in this unique and sparcely known patient cohort.

Clinical trial identification

Legal entity responsible for the study

Charité Medizinische Universitaet.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.